San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Rune Labs is raising $22,799,991.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Brian Pepin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rune Labs
The last decade has seen amazing progress in neuroscience, enabling researchers to envision a new generation of brain machine interfaces. These systems will be used to treat chronic diseases like Parkinsons, epilepsy, and Alzheimers. They will restore mobility to the paralyzed and speed recovery from a stroke. They may even allow us to control our mood and enhance our cognition. Rune Labs wants to build the software at the heart of these systems, and help accelerate the next wave of neuromodulation applications. Rune Labs has developed a medical platform designed to integrate with neuromodulation therapies to manage data ingestion, labeling, and availability. The company’s software platform helps partners in med-tech and pharma to ingest, organize and analyze large amounts of brain input and output data, all on state-of-the-art secure cloud infrastructure, enabling clients to utilize data from new sensing and stim neuromodulation devices for therapy development and clinical and commercial closed-loop and adaptive therapy applications.

To learn more about Rune Labs, visit http://runelabs.io/

Contact:
Brian Pepin, Chief Executive Officer
360-606-2929
https://www.linkedin.com/in/brian-pepin-73a87312/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved